A5036489497- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Viral Infections and Vectors
- Animal Virus Infections Studies
- Vaccine Coverage and Hesitancy
- Mosquito-borne diseases and control
- vaccines and immunoinformatics approaches
- Virology and Viral Diseases
- Viral gastroenteritis research and epidemiology
- Vector-Borne Animal Diseases
- Respiratory viral infections research
- COVID-19 epidemiological studies
- Viral Infections and Immunology Research
- Rabies epidemiology and control
- Influenza Virus Research Studies
- Plant Virus Research Studies
- Viral Infections and Outbreaks Research
- RNA Research and Splicing
- Malaria Research and Control
- Bacteriophages and microbial interactions
- Retinal and Optic Conditions
- Herpesvirus Infections and Treatments
- Immunotherapy and Immune Responses
- Poxvirus research and outbreaks
ICMR-National Institute of Virology
2018-2024
Indian Council of Medical Research
2021
Centers for Disease Control and Prevention
2018
Academy of Scientific and Innovative Research
2015-2016
National Chemical Laboratory
2011-2016
Abstract The drastic rise in the number of cases Maharashtra, India has created a matter concern for public health experts. Twelve isolates VUI lineage B.1.617 were propagated VeroCCL81 cells and characterized. Convalescent sera COVID-19 recipients BBV152 (Covaxin) able to neutralize B.1.617.
SARS-CoV-2 variant of concern mainly Delta and Beta is global public health due to its impact on existing vaccines. Here, we assessed the neutralization sera from COVID-19 recovered cases BBV152 vaccinees against variants. vaccine found confer significant protection both
From March to June 2021, India experienced a deadly second wave of COVID-19, with an increased number post-vaccination breakthrough infections reported across the country. To understand possible reason for these breakthroughs, we collected 677 clinical samples (throat swab/nasal swabs) individuals from 17 states/Union Territories country who had received two doses (n = 592) and one dose 85) vaccines tested positive COVID-19. These cases were telephonically interviewed data analyzed. A total...
Abstract The COVID-19 pandemic is a global health crisis that poses great challenge to the public system of affected countries. Safe and effective vaccines are needed overcome this crisis. Here, we develop assess protective efficacy immunogenicity an inactivated SARS-CoV-2 vaccine in rhesus macaques. Twenty macaques were divided into four groups five animals each. One group was administered placebo, while three immunized with different candidates BBV152 at 0 14 days. All challenged fourteen...
The availability of a safe and effective vaccine would be the eventual measure to deal with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) threat. Here, we have assessed immunogenicity protective efficacy inactivated SARS-CoV-2 candidates BBV152A, BBV152B, BBV152C in Syrian hamsters. Three dose vaccination regimes induced significant titers SARS-CoV-2-specific IgG neutralizing antibodies. BBV152A BBV152B remarkably generated quick robust immune response. Post-SARS-CoV-2...
ABSTRACT Background The recent emergence of new SARS-CoV-2 lineage B.1.617 in India has been associated with a surge the number daily infections. This variant combination specific mutations L452R, E484Q and P681R reported to possibly enhance transmissibility likelihood escaping immunity. We investigated viral load pathogenic potential B.1.617.1 Syrian golden hamsters. Methods Two groups hamsters (9 each) were inoculated intranasally SARS CoV-2 isolates, B.1 (D614G) respectively. animals...
We report here a Nipah virus (NiV) outbreak in Kozhikode district of Kerala state, India, which had caused fatal encephalitis 12-year-old boy and the response, led to successful containment disease related investigations. Quantitative real-time reverse transcription (RT)-PCR, ELISA-based antibody detection, whole genome sequencing (WGS) were performed confirm NiV infection. Contacts index case traced isolated based on risk categorization. Bats from areas near epicenter sampled for throat...
We have isolated the new severe acute respiratory syndrome coronavirus-2 variant of concern 202 012/01 from positive coronavirus disease 2019 cases that travelled UK to India in month December 2020. This emphasizes need for strengthened surveillance system limit local transmission this variant.
B.1.617 is becoming a dominant Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) lineage worldwide with many sublineages, of which B.1.617.2 designated as variant concern. The pathogenicity (Delta) and B.1.617.3 SARS-CoV-2 was evaluated compared that B.1, an early virus isolate D614G mutation in Syrian hamster model. Viral load, antibody response, lung disease were studied. There no significant difference the shedding pattern among these variants. High levels sub genomic RNA...
The number of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases is increasing in India. This study looks upon the geographic distribution virus clades and variants circulating different parts India between January August 2020. NPS/OPS from representative positive states union territories were collected every month through VRDLs country analyzed using next-generation sequencing. Epidemiological analysis 689 SARS-CoV-2 clinical samples revealed GH GR to be predominant northern...
SARS-CoV-2 Omicron variant is rampantly spreading across the globe. We assessed pathogenicity and immune response generated by BA.1.1 sub-lineage of [Omicron (R346K) variant] in 5 to 6-week old Syrian hamsters compared observations with that Delta infection.Virus shedding, organ viral load, lung disease were sequentially assessed.The characteristics found be similar infection like replication respiratory tract interstitial pneumonia. The infected demonstrated lesser body weight reduction RNA...
India introduced BBV152/Covaxin and AZD1222/Covishield vaccines in January 2021. We estimated the effectiveness of these against severe COVID-19 among individuals aged ≥45 years.We did a multi-centric, hospital-based, case-control study between May July Cases were patients, controls negative from 11 hospitals. Vaccine (VE) was for complete (2 doses ≥ 14 days) partial (1 dose 21 vaccination; interval two vaccine vaccination Delta variant. used random effects logistic regression model to...
The apprehension of needles related to injection site pain, risk transmitting bloodborne pathogens, and effective mass immunization have led the development a needle-free system (NFIS). Here, we evaluated efficacy NFIS needle (NIS) for delivery immunogenicity DNA vaccine candidate ZyCoV-D in rhesus macaques against SARS-CoV-2 infection. Briefly, 20 were divided into 5 groups (4 animals each), that is, I (1 mg dose by NIS), II (2 III NFIS), IV NFIS) V (phosphate-buffer saline [PBS])....
Abstract Recently, multiple SARS-CoV-2 variants have been detected across the globe. The recent emergence of B.1.617 lineage has created serious public health problem in India. high transmissibility was observed with this which led to daily increase number infections. Apparently, sub-lineage B.1.617.2 slowly dominated other including B1617.1, B.617.3 and B.1.1.7. With this, World Health Organization described as variant concern. Besides concern B.1.351 also reported from India, known...
Abstract Background In June 2019, Nipah virus (NiV) infection was detected in a 21-year-old male (index case) of Ernakulum, Kerala, India. This study undertaken to determine if NiV circulation Pteropus species ( spp) those areas where the index case had visit history 1 month. Methods Specialized techniques were used trap medius bats (random sampling) vicinity area. Throat and rectal swabs samples 141 along with visceral organs 92 collected detect presence by real-time reverse...
The study demonstrated that the breakthrough cases and COVID-19 recovered individuals with one or two doses of Covishield™ vaccine had relatively higher neutralizing responses against Delta variant in comparison to participants who were administered either Covishield™.
The neutralizing antibody responses were significantly elevated after 3rd dose of BBV152/Covaxin against the B.1 (19.11 fold) variant including Delta (16.51 fold), Beta (14.70 and Omicron (18.53 Variants concern in comparison with two vaccine, providing assurance a protective immune response booster recipients.
Background During the second wave of COVID-19 pandemic, outbreaks Zika were reported from Kerala, Uttar Pradesh, and Maharashtra, India in 2021. The Dengue Chikungunya negative samples retrospectively screened to determine presence virus different geographical regions India. Methods May October 2021, clinical 1475 patients, across 13 states a union territory re-tested for Dengue, by CDC Trioplex Real time RT-PCR. rRTPCR positive further with anti-Zika IgM Plaque Reduction Neutralization...